Video

Dr. Ruan on the Incidence of MCL

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the incidence of mantle cell lymphoma (MCL).

MCL is a rare subtype of B-cell non-Hodgkin lymphoma (NHL), says Ruan. In North America, MCL occurs in approximately 5% to 6% of new patients diagnosed with NHL.

Moreover, the disease tends to affect older patients, Ruan explains. The median age of patients who receive a diagnosis of MCL is 65 years.

Within the past decade, the MCL paradigm has expanded to include multiple new treatment options, Ruan says. These therapies have greatly improved survival for patients in this population.

Despite these advances, patients with MCL remain in need of additional therapies to further prolong survival, concludes Ruan.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center